Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV
Clinical and Translational Science · 2025-09 · 18 (9)
DOI: 10.1111/cts.70331 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 15.09.2025. Verfasst von Gillian Gillespie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
MK‐8527 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development. Two Phase 1 trials evaluated single (trial A) and multiple (trial B) ascending doses of MK‐8527 in adults without HIV. In trial A, 34 participants were assigned to 1 of 4 panels and randomized to receive single oral doses of MK‐8527 (0.5–200 mg) or placebo after fasting, over 3 dosing periods; 25 mg was assessed after a high‐fat meal. In trial B, 32 participants were randomized to receive 3 once‐weekly (QW) oral doses of MK‐8527 (between 5 and 40 mg) or placebo. Safety and pharmacokinetics (PK) of MK‐8527 and MK‐8527‐triphosphate (TP) were assessed. MK‐8527 was generally well tolerated with no serious adverse events. Plasma exposure of MK‐8527 increased approximately dose‐proportionally, and intracellular exposure of MK‐8527‐TP was slightly less than dose‐proportional over administered doses between 5 and 200 mg. Participants who received MK‐8527 with a meal showed a 41% decrease in C max with no effect on AUC 0–168 , and a 20%, 22%, and 58% increase in intracellular MK‐8527‐TP C max , C 168 , and AUC 0–168 , respectively. Across QW doses, plasma MK‐8527 median T max ranged from 0.5 to 1 h, and t 1/2 was 24–81 h; MK‐8527‐TP median T max ranged from 10 to 24 h on Day 15, and geometric mean apparent t 1/2 was 216–291 h. Accumulation of intracellular MK‐8527‐TP was modest (accumulation ratios [Day 15/Day 1] for C max and AUC 0–168 ranged from 1.1 to 1.6; C 168 from 1.2 to 2.4). Single and multiple QW doses of MK‐8527 were generally well tolerated in adults without HIV. The safety and PK profiles of MK‐8527 support continued clinical development. Trial Registration: EudraCT numbers: 2016‐004647‐36 (trial A); 2018‐000846‐20 (trial B)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, USA.
- MSD Belgium, Brussels, Belgium.
- SGS, Life Science Services, Antwerp, Belgium.
- Ghent University Hospital, Ghent, Belgium.
ORCID-Profile: Gillian Gillespie, Russ P Carstens, Xiaowei Zang, Ryan Vargo, Yash Kapoor, Arinjita Bhattacharyya, Tom Reynders, Randolph P Matthews, S Aubrey Stoch, Marian Iwamoto
Zitieren
APA
Gillespie, G., Carstens, R. P., Zang, X., Vargo, R., Kapoor, Y., Bhattacharyya, A., Denef, J. F., Reynders, T., Vanhoutte, F., Rottey, S., Matthews, R. P., Stoch, S. A., & Iwamoto, M. (2025). Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV. Clinical and Translational Science, 18(9). https://doi.org/10.1111/cts.70331
Vancouver
Gillespie G, Carstens RP, Zang X, Vargo R, Kapoor Y, Bhattacharyya A, et al. Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV. Clinical and Translational Science. 2025;18(9). doi:10.1111/cts.70331
BibTeX
@article{Gillespie2025,
author = {Gillespie, Gillian and Carstens, Russ P and Zang, Xiaowei and Vargo, Ryan and Kapoor, Yash and Bhattacharyya, Arinjita and Denef, Jean-Francois and Reynders, Tom and Vanhoutte, Frédéric and Rottey, Sylvie and Matthews, Randolph P and Stoch, S Aubrey and Iwamoto, Marian},
title = {Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {9},
doi = {10.1111/cts.70331}
}
EUVIMED